It depends on the standard you follow. As of September 2026, BillionToOne, Inc. (BLLN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.84% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.6% / 30% · Interest income / Revenue 3.99% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.84% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.6% / 33% · Receivables / Mkt Cap (36m) 1.82% / 49% · Interest income / Revenue 3.99% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 1.84% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.6% / 33.33% · Receivables / Mkt Cap (24m) 1.82% / 33.33% · Interest income / Revenue 3.99% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 12.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 75.9% / 33.33% · Receivables / Avg Assets (4Q) 9.42% / 33.33% · Interest income / Revenue 3.99% / 5% | Fail |
| FTSE | Debt / Total Assets 11.7% / 33.33% · (Cash+ST Inv) / Total Assets 73.8% / 33.33% · (Cash+Recv) / Total Assets 85.4% / 33.33% · Interest income / Revenue 3.99% / 5% | Fail |
It depends on the standard you follow. As of September 2026, BillionToOne, Inc. (BLLN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. BillionToOne, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.99% of each dividend: BillionToOne, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
BillionToOne, Inc. (NASDAQ: BLLN) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $4.6B. The Maz Rating grades it against the other companies in its sector.
BillionToOne, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $96.31, BillionToOne, Inc. trades at 93.8x trailing earnings, 10.5x sales and 8.0x book value, with an EV/EBITDA of 70.7. Over the last twelve months it generated about $437M of revenue and $49M of net income. It runs a gross margin of 71.4%, an operating margin of 10.2% and a net margin of 11.3%. It shows return on equity of 9.5%, return on invested capital of 6.3% and a free cash flow yield of 0.7%. On the balance sheet: a debt-to-equity ratio of 0.25 and a current ratio of 11.25. Over the past 52 weeks the share price ranged from $61.96 to $150.44, with a beta of 0.34.
BillionToOne, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 4 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.